Multicentric reticulohistiocytosis (MRH): case report with review of literature between 1991 and 2014 with in depth analysis of various treatment regimens and outcomes

SpringerPlus

Table 1 Summary of the different treatments used with relative benefit

Medical treatments and indication	n total	n (%) for score 3 = resolution of the condition	n (%) for score 2 = improvement without resolution	n (%) for score 1 = no benefit/condition remained same	n (%) for score 0 = worse than prior to treatment
Methotrexate for arthritis	25	7 (28)	11 (44)	3 (12)	4 (16)
Methotrexate for skin	26	10 (38)	10 (28)	3 (11)	3 (11)
Hydroxychloroquine arthritis	7	0 (0)	1 (14)	3 (43)	3 (43)
Hydroxychloroquine skin	7	0 (0)	1 (14)	3 (43)	3 (43)
Thalidomide	1		1 (100)
Sulfasalazine arthritis	1				1 (100)
Sulfasalazine skin	1				1 (100)
Leflunomide arthritis	2	2 (100)
Leflunomide skin	2	2 (100)
Azathioprine arthritis	2	1 (50)		1 (50)
Azathioprine skin	2	1 (50)	1 (50)
Cyclophosphamide arthritis	10	2 (20)	4 (40)	4 (40)
Cyclophosphamide skin	11	3 (27)	5 (45)	3 (27)
Cyclosporine arthritis	1	1 (100)
Cyclosporine skin	2	1 (50)		1 (50)
Etanercept arthritis	6	3 (50)	2 (33)	1 (17)
Etanercept skin	6	3 (50)	2 (33)	1 (17)
Adalimumab arthritis	2	2 (100)
Adalimumab skin	2	2 (100)
Infliximab arthritis	3	1 (33)	2 (67)
Infliximab skin	3	1 (33)	2 (67)
Alendronate arthritis	4	1 (25)	2 (50)	1 (25)
Alendronate skin	4	2 (50)	1 (25)	1 (25)
Zolendronic acid arthritis	3	1 (33)	2 (67)
Zolendronic acid skin	2	1 (50)	1 (50)
Pamidronate arthritis	1		1 (100)
Pamidronate skin	1			1 (100)
Chlorambucil arthritis	1				1 (100)
Chlorambucil skin	1				1 (100)
Sodium aurothiomalate	1			1 (100)
Naproxen	1	1 (100)
Prednisone alone for arthritis	2		2 (100)
Prednisone alone for skin	2	1 (50)	1 (50)